Basic Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. May 21, 2005; 11(19): 2922-2926
Published online May 21, 2005. doi: 10.3748/wjg.v11.i19.2922
Figure 1
Figure 1 Immunocytochemistry analysis of α-SMA of HSCs subjected to different treatment of tetrandrine (magnification ×200). A: control; B: tetrandrine 0.25 mg/L; C: tetrandrine 0.5 mg/L; D: tetrandrine 1 mg/L; E: tetrandrine 2 mg/L.
Figure 2
Figure 2 Expression of α-SMA in culture-activated HSCs. bP<0.01 vs control group. dP<0.01 vs tetrandrine 0.25 mg/L group. fP<0.01 vs tetrandrine 0.25, 0.5 mg/L groups.
Figure 3
Figure 3 RT-PCR determination of Smad 7 and TGF-β1 mRNA expressions. Lane 1: 100-bp marker, lane 2: control group, lanes 3-6: treatment with tetrandrine at 0.25, 0.5, 1.0, 2.0 mg/L, respectively.
Figure 4
Figure 4 Radioimmunoassay of LN and PCIII. aP<0.05 vs control group.
Figure 5
Figure 5 Immunoblot analysis for Smad 7. C: control group, Tet-1: treatment with tetrandrine at 1 mg/L, M: protein marker.